Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Several safety and mechanistic statements align with the provided tramadol hydrochloride extended-release label excerpts (e.g., serotonin syndrome risk, seizure risk, life-threatening respiratory depression, mu-opioid receptor binding, and NE/5-HT reuptake inhibition). However, multiple claims are either not supported by the provided label text (e.g., opioid dosing frequency for immediate-release and twice-daily ER, manufacturing/patent/pricing assertions) or are only generally stated without label-specific support. The comparison appears mixed across the set of claims.
Category Scores
Accurate Statements
Tramadol binds to mu-opioid receptors in the central nervous system.
12.1 Mechanism of Action: binding of parent and M1 metabolite to mu-opioid receptors.
Tramadol inhibits the reuptake of norepinephrine and serotonin.
12.1 Mechanism of Action: inhibitor of reuptake of norepinephrine and serotonin; weak inhibition of reuptake.
The risks of dependence, addiction, and overdose with tramadol are especially increased when used at high doses or for prolonged periods.
Limitation of Use: risks of addiction, abuse, misuse, overdose, and death; reserve opioid analgesics for patients for whom alternatives are inadequate (provided excerpt does not specify the high-dose/prolonged rationale, but the overall risk framing is label-consistent).
Common side effects of tramadol include nausea, constipation, dizziness, drowsiness, and headache.
6.1 Clinical Trials Experience/Table 1 excerpt described includes headache, nausea, somnolence, dizziness, constipation, vomiting.
Serious side effects of tramadol can include respiratory depression.
5.2 Life-Threatening Respiratory Depression; and 6 Adverse Reactions reference to Life-Threatening Respiratory Depression.
Serious side effects of tramadol can include serotonin syndrome, particularly when combined with other serotonergic drugs.
5.9 Serotonin Syndrome Risk: cases reported, particularly during concomitant use with serotonergic drugs.
Serious side effects of tramadol can include seizures.
5.10 Increased Risk of Seizures; and 6 Adverse Reactions reference to Seizures.
The risk of serious side effects (serotonin syndrome and seizures) with tramadol may be higher in certain patient populations or when used concurrently with other medications.
5.9 (serotonergic concomitant use) and 5.10 (increased risk with doses above recommended range and with concomitant seizure-threshold-lowering drugs/SSRIs/SNRIs, etc.).
Tramadol’s Schedule IV classification is due to its potential for abuse and dependence.
Supported indirectly by the provided label excerpt theme of addiction/abuse/misuse risks in Limitation of Use (no DEA Schedule rationale text was provided in the excerpts).
Unsupported Statements
Tramadol is an opioid pain medication used to treat moderate to moderately severe pain.
Provided label excerpts for tramadol ER indicate management of severe and persistent pain requiring an opioid analgesic; 'moderate to moderately severe' is not supported by the supplied text.
Tramadol is available in immediate-release (IR) and extended-release (ER) formulations.
The provided excerpts are for extended-release capsules; no explicit IR vs ER availability statement was included in the supplied label text.
Immediate-release tramadol is typically taken every four to six hours as needed for pain.
No immediate-release dosing frequency/PRN regimen is provided in the supplied label excerpts.
Extended-release tramadol is designed for around-the-clock pain management and is usually taken once or twice daily.
The provided label excerpts state extended-release capsules are administered orally once daily and are not indicated as an as-needed (prn) analgesic; 'once or twice daily' and 'around-the-clock/PRN' framing are not supported.
Tramadol is manufactured by numerous pharmaceutical companies.
No manufacturing-company or market-structure information is present in the supplied label excerpts.
Tramadol is available as a generic medication, with many companies producing their own versions.
No generic availability/manufacturer-count/pricing statements are present in the supplied label excerpts.
Tramadol’s primary patents have expired, allowing for generic manufacturing.
Patent-expiration statements are not present in the supplied label excerpts.
Some specific formulations or delivery methods of tramadol might have later-expiring patents.
Patent-expiration statements are not present in the supplied label excerpts.
Norepinephrine and serotonin are neurotransmitters that play a role in pain signaling.
The provided label excerpts confirm pharmacologic actions (reuptake inhibition) but do not state that NE/serotonin 'play a role in pain signaling.'
The risks of dependence, addiction, and overdose with tramadol are especially increased when used at high doses or for prolonged periods.
The label excerpts provided do not specify 'high doses or prolonged periods' as the reason for increased dependence/addiction/overdose risk (they do specify seizure risk increases with doses above recommended range).
The Schedule IV classification of tramadol imposes certain prescribing and dispensing regulations.
The provided label excerpts do not include DEA Schedule-specific regulatory descriptions.
The market for tramadol is substantial due to its widespread use in managing moderate pain.
Market-size/widespread-use and 'moderate pain' claim are not present in the provided label excerpts.
As a generic medication, tramadol market competition among multiple manufacturers generally leads to lower prices compared to branded drugs.
Price/market-competition assertions are not present in the provided label excerpts.
Tramadol has potential for abuse and risk of addiction.
The supplied label excerpt themes include 'risks of addiction, abuse, misuse' but the claim is not tied to an explicit statement within the provided text beyond the Limitation of Use fragment; treated as partially unsupported due to lack of explicit phrasing in the excerpt set.
Compared to stronger opioids like morphine or oxycodone, tramadol is generally considered to have a lower risk of respiratory depression and abuse.
No comparative statements to other opioids are present in the supplied label excerpts.
Compared to NSAIDs or acetaminophen, tramadol acts on opioid receptors.
The label confirms tramadol is an opioid agonist, but it does not include a comparison versus NSAIDs/acetaminophen.
Tramadol has a different side effect profile and risk of dependence compared with NSAIDs or acetaminophen.
No comparative NSAID/acetaminophen risk statements are present in the supplied label excerpts.
Contradictions
Low
AI Statement
Extended-release tramadol is designed for around-the-clock pain management and is usually taken once or twice daily.
Label Reference
2.1 Important Dosage and Administration Instructions: 'Tramadol Hydrochloride Extended-Release Capsules are administered orally once daily.' Also Limitation of Use: 'Tramadol Hydrochloride Extended-Release Capsules are not indicated as an as-needed (prn) analgesic.'
Important Omissions
For extended-release tramadol, the label includes critical administration and dosing-safety instructions (e.g., prescribe only by knowledgeable professionals; do not use concomitantly with other tramadol products; do not exceed 300 mg/day; swallow whole—do not break/chew/split/dissolve; taper rather than abrupt discontinuation in physical dependence).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Most major serious risks mentioned (respiratory depression, serotonin syndrome, seizures) are supported by the provided tramadol ER label excerpts. However, dosing/administration claims for IR/ER (including ER frequency 'once or twice daily' and PRN framing 'around-the-clock') are not supported and could mislead about safe use. Additional non-label statements (patents/market/pricing) do not directly affect clinical safety but indicate low label fidelity overall.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Mostly Aligned
Primary Issue
Several claims are not supported by the provided tramadol ER prescribing-information excerpts, especially non-label manufacturing/patent/market assertions and incorrect/not-supported dosing frequency and PRN framing for extended-release.
Suggested Improvement
Restrict claims to what is explicitly supported in the supplied tramadol hydrochloride extended-release label excerpts: include ER once-daily administration (not twice daily), avoid PRN indications, and remove or clearly separate non-label assertions (manufacturers, patents, pricing/market).